We only have this paper's title and publication details.
Read it at the sourceSwitching to a biosimilar natalizumab demonstrates safety and satisfaction in multiple sclerosis, suggesting its viability as an alternative treatment.
Switching from originator to biosimilar natalizumab
No takes yet. Share an insight, caveat, or question.
Gelissen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: